Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 16/20 | 0.79 |
| ▸ | CDK2 | P24941 | 13/20 | 0.79 |
| ▸ | CDK7 | P50613 | 11/20 | 0.79 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.79 |
| ▸ | CDK5 | Q00535 | 10/20 | 0.79 |
| ▸ | CDK4 | P11802 | 8/20 | 0.79 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.79 |
| ▸ | CCND1 | P24385 | 8/20 | 0.79 |
| ▸ | CCNH | P51946 | 8/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.79 |
| ▸ | CDK9 | P50750 | 4/20 | 0.79 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.79 |
| ▸ | CLK2 | P49760 | 2/20 | 0.79 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.79 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.79 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.79 |
| ▸ | CSNK1G1 | Q9HCP0 | 2/20 | 0.79 |
| ▸ | CCNK | O75909 | 2/20 | 0.79 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.79 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14403894 | 0.92 | CDK1 (0.88) | CDK1CDK2CDK7CCNE1CDK5 | |
| SCHEMBL16366290 | 0.91 | CDK1 (0.78) | CDK1CDK2CDK7CCNE1CDK5 | |
| SCHEMBL13497862 | 0.91 | CDK1 (0.78) | CDK1CDK2CDK7CCNE1CDK5 | |
| (S)-Roscovitine SCHEMBL2907488 | 0.88 | CDK1 (1.00) | CDK1CDK2CDK7CCNE1CDK5 | |
| (Rs)-Roscovitine SCHEMBL15163619 | 0.88 | CDK1 (1.00) | CDK1CDK2CDK7CCNE1CDK5 | |
| (Rs)-Roscovitine SCHEMBL172593 | 0.88 | CDK1 (1.00) | CDK1CDK2CDK7CCNE1CDK5 | |
| Seliciclib SCHEMBL94728 | 0.88 | CDK1 (1.00) | CDK1CDK2CDK7CCNE1CDK5 | |
| (S)-Roscovitine SCHEMBL29415376 | 0.88 | CDK1 (1.00) | CDK1CDK2CDK7CCNE1CDK5 | |
| SCHEMBL19705771 | 0.87 | CDK1 (0.80) | CDK1CDK2CDK7CCNE1CDK5 | |
| SCHEMBL23198590 | 0.86 | CDK1 (0.85) | CDK1CDK2CDK7CCNE1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000881-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-01-05 | — | — | US | disclosed |
| EP-3786164-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | Ting Therapeutics LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3310783-B1 | COMPOSITIONS FOR THE PREVENTION OF HEARING LOSS | TING THERAPEUTICS LLC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200179397-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2020-06-11 | — | — | US | disclosed |
| US-20180161340-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2018-06-14 | — | — | US | disclosed |
| US-20180161340-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2018-06-14 | — | — | US | disclosed |
| WO-2016205806-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2014204856-A1 | FATTY ACID ANTICANCER DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| US-20100048890-A1 | CONJUGATED SMALL MOLECULES | DISCOVERX CORPORATION | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000881-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | CDK2, CDK5, CDK20 | CDK1 6/4885CDK2 1/4885CDK7 25/4885 |
| US-20200179397-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | CDK2, CDK5, CDK20 | CDK1 6/4885CDK2 1/4885CDK7 25/4885 |
| US-20100048890-A1 | CONJUGATED SMALL MOLECULES | ERBB2, ALK, ACP1 | CDK1 768/4885CDK2 510/4885CDK7 642/4885 |
| US-20180161340-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | CDK2, CDK5, CDK20 | CDK1 6/4885CDK2 1/4885CDK7 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.